WO2005112995A1 - Vaccin associe inactive pour la maladie respiratoire du porc et procede de production associe - Google Patents

Vaccin associe inactive pour la maladie respiratoire du porc et procede de production associe Download PDF

Info

Publication number
WO2005112995A1
WO2005112995A1 PCT/KR2005/001207 KR2005001207W WO2005112995A1 WO 2005112995 A1 WO2005112995 A1 WO 2005112995A1 KR 2005001207 W KR2005001207 W KR 2005001207W WO 2005112995 A1 WO2005112995 A1 WO 2005112995A1
Authority
WO
WIPO (PCT)
Prior art keywords
vaccine
virus
cell
inactivated
disease
Prior art date
Application number
PCT/KR2005/001207
Other languages
English (en)
Inventor
In-Joong Yoon
Sung-Min Lee
Sung-Sik Yoo
Original Assignee
Choongang Vaccine Laboratory Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Choongang Vaccine Laboratory Co., Ltd. filed Critical Choongang Vaccine Laboratory Co., Ltd.
Publication of WO2005112995A1 publication Critical patent/WO2005112995A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Definitions

  • the present invention relates to a vaccine for porcine respiratory diseases. Specifically, the present invention relates to an inactivated mixed (combined) vaccine for porcine respiratory diseases.
  • porcine respiratory diseases have been serious problem which results in severe economic loss to farms.
  • PMS post-weaning multisystemic wasting syndrome
  • PRDC porcine respiratory disease complex
  • various vaccines have been introduced.
  • a vaccine for any one of conditions was not effective in many cases.
  • a few of mixed vaccines were developed and applied at several farms. The mixed vaccines, however, were not
  • PRRS Reproductive & Respiratory Syndrome
  • the Glasser's disease in a pig is highly infective to a 2 ⁇ 4 month
  • This disease develops by the infection of a pathogenic microbial, which
  • a pig can be activated by Mycoplasma hyopneumoniae or PRRS virus.
  • This disease mainly
  • the PRRS virus is a RNA virus which has envelope and
  • pneumonia makes the affected pig to be very sensitive to secondary infections of other respiratory diseases, for example, Glasser's disease,
  • This invention is for providing a mixed (combined) vaccine for
  • invention is for providing an inactivated mixed vaccine for preventing
  • PRRS reproductive and respiratory syndrome
  • Another object of this invention is to provide an inactivated mixed
  • porcine respiratory diseases, PMWS and PRDC of a growing-finishing pig porcine respiratory diseases, PMWS and PRDC of a growing-finishing pig.
  • object of this invention is to provide a novel method of
  • the vaccine for Glasser's disease is the vaccine for Glasser's disease
  • the vaccine for PRRS was prepared using MN-HS (Minnesota)
  • PRRSV Korean isolate CNV-1, Korean J. Vet Res (1999) 39(2):
  • CPE cytopathic effect
  • the mixed vaccine composition of this invention preferably a
  • the composition comprises in a range of 20 - 30% (vol/vol) vaccine components.
  • Haemophilus parasuis S4 strain (0.D 0.4 - 0.5 at 410 nm)
  • Haemophilus parasuis S5 strain (0.D 0.4 ⁇ 0.5 at 410 nm)
  • Mycoplasma hyopneumoniae J/101 (0.D 0.
  • antibody titer to PRRS virus provides more accurate antibody titer.
  • finished stage of marketed pigs daily weight
  • the average weight of the pigs given with the mixed vaccine of this invention was in a range of 3.1-4.2
  • the mixed vaccine of this invention was higher than that of the pigs
  • Fig. 1 to Fig. 3 show examples of pneumonia scores.
  • Fig. 1 is an example of pneumonia, and shows percentage of each lobe for entire normal lung.
  • Fig. 2 is an example of pneumonia, and shows lung lesion having 12% of lobe score.
  • Fig. 3 is an example of pneumonia, and shows lung lesion having 20% of lobe score.
  • Example 1 Isolation and culturing virus
  • TSB Tryptic Soy Broth
  • NAD ⁇ -Nicotinamide adenine dinucleotide 45 ⁇ g/mi , yeast extract 0.5%
  • J/101 strain obtained from National Veterinary Research and Quarantine Service, which causes swine enzootic pneumonia, was delivered in
  • mycoplasma medium (table 1) and was incubated. After the isolation, the incubated strain was in freeze-drying and cryopreservation at -80 ° C.
  • mycoplasma medium (table 1) in 1/3 volume of the medium, and incubated
  • the swine lung macrophage cell the STL cell, or the
  • A-72 cell was suspended in a cell culture medium (table 2).
  • the cell culture medium (table 2).
  • example 1 were delivered in a TSB medium including ⁇ -NAD ( ⁇ -
  • Nicotinamide adenine dinucleotide 45 ⁇ g/ml , yeast extract 0.5% and were
  • PRRS virus MN-HS or CNV-1 was inoculated
  • UV spectrophotometer UV spectrophotometer.
  • the inactivated PRRS virus was 1/10 diluted, and
  • STL wine testis cell line
  • the virus content was determined with the appearance of CPE following the PRRS virus inoculation.
  • virus content was over 10 6,0 TCIDso/m ⁇ .
  • Example 3 Preparation of inactivated mixed vaccine Strain isolation, disease causing agent isolation and inactivation
  • vaccine components were 30% (vol/vol) of the whole mixed vaccine
  • Haemophilus parasuis S4 (at 410 nm, O.D 0.45), Haemophilus parasuis S5 (at 410 nm, O.D 0.45), Mycoplasma hyopneumoniae J/101 (at 410 nm, O.D 0.1) and PRRS MN-HS (10 6 '°TCID 50 /ml) .
  • the vaccine composition it was filtered with copper net. Then, the
  • the composition did not have any taste and smell.
  • the vaccine sample in each lot was transferred to Thioglycollate medium (Thio), Nutrient agar
  • NA Nutrient broth
  • NB Nutrient broth
  • Thioglycollate medium Thioglycollate medium (Thio), Nutrient agar (NA) and Nutrient broth (NB),
  • mice weighing 13 g and 10 mice weighing 15 g were used.
  • Respective vaccine samples (0.5 ml, lot no. 1-3) of example 3 were delivered intraperitoneally to 5 mice weighing 13 g and 5 mice weighing 15 g.
  • respective vaccine samples (0.5 ml, lot no. 1-3) of example 3 were delivered subcutaneously to 5 mice weighing 13 g and to 5 mice weighing 15 g.
  • the vaccinated mice were monitored in comparison to 5 untreated control mice. All the mice, which were injected with the mixed vaccine of this invention, survived during the monitoring period (table 6).
  • Respective 12 guinea pigs weighing 300 g and 350 g were used in this experiment. Respective 4 guinea pigs weighing 300 g and 4 guinea pigs weighing 350 g were injected intramuscularly by the respective vaccine sample of example 3 (0.1 ml). And respective 4 guinea pigs weighing 300 g and 4 guinea pigs weighing 350 g were injected intradermally by the respective vaccine sample of example 3 (0.1 ml). And
  • mice 3 (0.1 ml). The vaccinated mice were monitored in comparison to 4
  • the mixed vaccine (2.0 ml, Lot no. 1) of the example 3.
  • five piglets were injected through neck muscle using the mixed vaccine (2.0 ml,
  • piglets showed clinical symptom, for example, anorexia, respiratory
  • Mycoplasma hyopneumoniae increased 80-320 fold after 2 weeks from the
  • virus was not more than 2 fold after 2 weeks from the first injection, and was in a range of 4-8 fold after 4 weeks from the second injection, respectively. Not more than 10 fold neutralizing antibody titer was detected for the untreated control pigs (table 9).
  • Example 6 Detection of neutralizing antibody titer in a guinea pig
  • guinea pigs (300-350 g) were used in this experiment. 10 of them were inoculated intramuscularly using 1 ml of the mixed vaccine of this invention, and were additionally injected with the same amount of the mixed vaccine after three weeks from the first injection. 2 of the guinea pigs were used as controls. 2 weeks after the second injection,
  • the blood samples of pigs were collected before the first injection, after three weeks from the first injection, after 2
  • ⁇ -MEM cell culture medium
  • guinea pig can be used as an excellent specimen for
  • the mixed vaccine of this invention was monitored while being stored in a refrigerator for a long time.
  • the vaccine sample was stored in a range of 2 ⁇ 7 ° C in a dark cold place.
  • 1.0 ml of it was injected through neck muscle to 1-week-old healthy piglets, which were antibody negative to Haemophilus parasuis, Mycoplasma hyopneumoniae and PRRS virus, every 3 months from the date of preparation for 21 months.
  • 2.0 ml of vaccine sample was injected to the piglets.
  • sera was collected and ELISA antibody titer (H. parasuis and M. hyopneumoniae) and neutralizing antibody titers were assayed.
  • the immunogenicity was effective and the stability was satisfactory until 21 months (table 15, 16, 17 and 18).
  • ELISA antibody titer for Haemophilus parasuis increased 80-160 fold after 2 weeks from the first injection, and increased 320-1,280 fold after 4 weeks from the second injection, respectively.
  • ELISA antibody titer for Mycoplasma hyopneumoniae increased 80-320 fold after 2 weeks from the
  • vaccine of this invention weigh in an average range of 1.5-2.0 kg more
  • the piglets inoculated with the mixed vaccine of this invention weigh in
  • lung lesion score was carried out in accordance with the known method
  • the mixed vaccine of this invention can effectively prevent
  • PRDC Pulcine Respiratory Disease Complex

Abstract

L'invention concerne un vaccin associé inactivé pour la prévention de la maladie respiratoire du porc. Le vaccin associé inactivé de l'invention qui comprend une certaine dose de souche S4 et S5 de Haemophilus parasuis, Mycoplasma hyopneumoniae, et de virus PRRS inactivés, permet de prévenir de manière efficace les maladies respiratoires du porc de type maladie de Glasser, pneumonie enzootique du porc et PRRS. En outre, le vaccin associé de l'invention peut prévenir la progression de la maladie respiratoire du porc en PRDC (complexe respiratoire du porc) et PMWS (syndrome de dépérissement post-sevrage multisystémique).
PCT/KR2005/001207 2004-04-26 2005-04-26 Vaccin associe inactive pour la maladie respiratoire du porc et procede de production associe WO2005112995A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2004-0028717 2004-04-26
KR20040028717 2004-04-26

Publications (1)

Publication Number Publication Date
WO2005112995A1 true WO2005112995A1 (fr) 2005-12-01

Family

ID=35428255

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2005/001207 WO2005112995A1 (fr) 2004-04-26 2005-04-26 Vaccin associe inactive pour la maladie respiratoire du porc et procede de production associe

Country Status (2)

Country Link
CN (1) CN1942204A (fr)
WO (1) WO2005112995A1 (fr)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1941903A1 (fr) * 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxie et traitement du PRDC
CN100419073C (zh) * 2006-09-28 2008-09-17 中国兽医药品监察所 猪喘气病活疫苗及其生产方法
CN101420975B (zh) * 2006-04-10 2012-06-27 英特威国际有限公司 抗支原体和prrsv的疫苗
US8475805B2 (en) 2007-09-04 2013-07-02 Boehringer Ingelheim Vetmedica, Inc. Methods of reducing concomitant infections in pigs with a PCV2 antigen
US8496940B2 (en) 2007-02-13 2013-07-30 Boehringer Ingelheim Vetmedica, Inc. Prevention and treatment of sub-clinical PCVD
CN103941001A (zh) * 2013-03-15 2014-07-23 河南省农业科学院 猪副嗜血杆菌快速检测试纸条
CN103941002A (zh) * 2013-03-15 2014-07-23 河南省农业科学院 猪丹毒杆菌抗原快速检测试纸条
US8865183B2 (en) 2006-12-15 2014-10-21 Boehringer Ingelheim Vetmedica, Inc. Treatment of pigs with PCV2 antigent
US9011872B2 (en) 2004-12-30 2015-04-21 Boehringer Ingelheim Vetmedica, Inc. PCV2 immunogenic compositions and methods of producing such compositions
US9011868B2 (en) 2005-12-29 2015-04-21 Boehringer Ingelheim Vetmedica, Inc. Use of a PCV2 immunogenic composition for lessening clinical symptoms in pigs
US9101561B2 (en) 2005-12-29 2015-08-11 Boehringer Ingelheim Vetmedica, Inc. Multivalent PCV2 immunogenic compositions and methods of producing such compositions
US9505808B2 (en) 2013-10-02 2016-11-29 Boehringer Ingelheim Vetmedica, Inc. PCV2 ORF2 protein variant and virus like particles composed thereof
US9561270B2 (en) 2009-09-02 2017-02-07 Boehringer Ingelheim Vetmedica, Inc. Methods of reducing virucidal activity in PCV-2 compositions and PCV-2 compositions with an improved immunogenicity
US9636389B2 (en) 2006-12-11 2017-05-02 Boehringer Ingelheim Vetmedica, Inc. Effective method of treatment of porcine circovirus and Lawsonia intracellularis infections
US9669086B2 (en) 2008-01-23 2017-06-06 Boehringer Ingelheim Vetmedica, Inc. PCV2 Mycoplasma hyopneumoniae immunogenic compositions and methods of producing such compositions
CN107589256A (zh) * 2017-09-30 2018-01-16 天津瑞普生物技术股份有限公司 副猪嗜血杆菌病4型、5型二价灭活疫苗效力的检验方法
US9919041B2 (en) 2004-12-30 2018-03-20 Boehringer Ingelheim Vetmedica, Inc. PCV2 immunogenic compositions and methods of producing such compositions
CN113907044A (zh) * 2021-11-09 2022-01-11 福建省连江县刘氏兔业养殖场 一种抗病猪品系的培育方法及其应用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101940786B (zh) * 2009-12-28 2012-08-29 华中农业大学 副猪嗜血杆菌免疫原性蛋白基因PilA的应用
CN102559531B (zh) * 2010-12-15 2014-03-19 武汉科前动物生物制品有限责任公司 一种副猪嗜血杆菌5型高密度发酵培养基及应用
CN103083655B (zh) * 2011-11-02 2015-08-26 普莱柯生物工程股份有限公司 预防和治疗猪圆环病毒2型、副猪嗜血杆菌和猪肺炎支原体感染的疫苗组合物及其制备方法
CN103961695B (zh) * 2013-02-06 2016-09-07 普莱柯生物工程股份有限公司 一种预防和治疗猪呼吸道综合征的疫苗组合物及其制备方法和应用
CN104096222B (zh) * 2013-04-08 2016-09-14 普莱柯生物工程股份有限公司 一种疫苗组合物及其制备方法和应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LIN J.H. ET AL: "Prospective effects of oral microencapsulated Mycoplasma hyopneumoniae vaccine prepared by co-spray drying method.", J. VET. MED. SCI., vol. 65, no. 1, 2003, pages 69 - 74 *
OLIVEIRA S. ET AL: "Haemophilus parasuis: new trends on diagnosis, epidemiology and control.", VET. MICROBIOL., vol. 99, no. 1, 2004, pages 1 - 12 *
TADJINE M. ET AL: "Development of a New Serological Test for Serotypnig Haemophilus parasuit Isolates and Determination of Their Prevalence in North America.", J. CLIN. MICROBIOL., vol. 42, no. 2, 2004, pages 839 - 840 *

Cited By (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9919041B2 (en) 2004-12-30 2018-03-20 Boehringer Ingelheim Vetmedica, Inc. PCV2 immunogenic compositions and methods of producing such compositions
US9011872B2 (en) 2004-12-30 2015-04-21 Boehringer Ingelheim Vetmedica, Inc. PCV2 immunogenic compositions and methods of producing such compositions
US10576142B2 (en) 2004-12-30 2020-03-03 Boehringer Ingelheim Vetmedica, Inc. PCV2 immunogenic compositions and methods of producing such compositions
US9925256B2 (en) 2005-12-29 2018-03-27 Boehringer Ingelheim Vetmedica, Inc. Multivalent PCV2 immunogenic compositions and methods of producing such compositions
US9987349B2 (en) 2005-12-29 2018-06-05 Boehringer Ingelheim Vetmedica, Inc. Use of a PCV2 immunogenic composition for lessening clinical symptoms in pigs
US10624963B2 (en) 2005-12-29 2020-04-21 Boehringer Ingelheim Vetmedica, Inc. Multivalent PCV2 immunogenic compositions and methods of producing such compositions
US9011868B2 (en) 2005-12-29 2015-04-21 Boehringer Ingelheim Vetmedica, Inc. Use of a PCV2 immunogenic composition for lessening clinical symptoms in pigs
US10568955B2 (en) 2005-12-29 2020-02-25 Boehringer Ingelheim Vetmedica, Inc. Use of a PCV2 immunogenic composition for lessening clinical symptoms in pigs
US9610345B2 (en) 2005-12-29 2017-04-04 Boehringer Ingelheim Vetmedica, Inc. Use of a PCV2 immunogenic composition for lessening clinical symptoms in pigs
US9669087B2 (en) 2005-12-29 2017-06-06 Boehringer Ingelheim Vetmedica, Inc. Use of a PCV2 immunogenic composition for lessening clinical symptoms in pigs
US9925255B2 (en) 2005-12-29 2018-03-27 Boehringer Ingelheim Vetmedica, Inc. Multivalent PCV2 immunogenic compositions and methods of producing such compositions
US9101561B2 (en) 2005-12-29 2015-08-11 Boehringer Ingelheim Vetmedica, Inc. Multivalent PCV2 immunogenic compositions and methods of producing such compositions
CN101420975B (zh) * 2006-04-10 2012-06-27 英特威国际有限公司 抗支原体和prrsv的疫苗
CN100419073C (zh) * 2006-09-28 2008-09-17 中国兽医药品监察所 猪喘气病活疫苗及其生产方法
US9636389B2 (en) 2006-12-11 2017-05-02 Boehringer Ingelheim Vetmedica, Inc. Effective method of treatment of porcine circovirus and Lawsonia intracellularis infections
US9517260B2 (en) 2006-12-15 2016-12-13 Boehringer Ingelheim Vetmedica, Inc. Treatment of pigs with PCV2 antigen
US8865183B2 (en) 2006-12-15 2014-10-21 Boehringer Ingelheim Vetmedica, Inc. Treatment of pigs with PCV2 antigent
WO2008081015A1 (fr) * 2007-01-03 2008-07-10 Boehringer Ingelheim Vetmedica, Inc. Traitement de prdc chez les porcs
US9522182B2 (en) 2007-01-03 2016-12-20 Boehringer Ingelheim Vetmedica, Inc. Prophylaxis and treatment of PRDC
EP3017829A1 (fr) * 2007-01-03 2016-05-11 Boehringer Ingelheim Vetmedica, Inc. Traitement de prdc chez les porcs
US10010604B2 (en) 2007-01-03 2018-07-03 Boehringer Ingelheim Vetmedica, Inc. Treatment of PRDC in pigs
EP1941903A1 (fr) * 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxie et traitement du PRDC
US9555092B2 (en) 2007-02-13 2017-01-31 Boehringer Ingelheim Vetmedica, Inc. Prevention and treatment of sub-clinical PCVD
US8496940B2 (en) 2007-02-13 2013-07-30 Boehringer Ingelheim Vetmedica, Inc. Prevention and treatment of sub-clinical PCVD
US9132187B2 (en) 2007-02-13 2015-09-15 Boehringer Ingelheim Vetmedica, Inc. Prevention and treatment of sub-clinical PCVD
US9132186B2 (en) 2007-09-04 2015-09-15 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
US8475805B2 (en) 2007-09-04 2013-07-02 Boehringer Ingelheim Vetmedica, Inc. Methods of reducing concomitant infections in pigs with a PCV2 antigen
US9669086B2 (en) 2008-01-23 2017-06-06 Boehringer Ingelheim Vetmedica, Inc. PCV2 Mycoplasma hyopneumoniae immunogenic compositions and methods of producing such compositions
US9561270B2 (en) 2009-09-02 2017-02-07 Boehringer Ingelheim Vetmedica, Inc. Methods of reducing virucidal activity in PCV-2 compositions and PCV-2 compositions with an improved immunogenicity
CN103941002B (zh) * 2013-03-15 2016-03-16 河南省农业科学院 猪丹毒杆菌抗原快速检测试纸条
CN103941001B (zh) * 2013-03-15 2016-03-16 河南省农业科学院 猪副嗜血杆菌快速检测试纸条
CN103941001A (zh) * 2013-03-15 2014-07-23 河南省农业科学院 猪副嗜血杆菌快速检测试纸条
CN103941002A (zh) * 2013-03-15 2014-07-23 河南省农业科学院 猪丹毒杆菌抗原快速检测试纸条
US9505808B2 (en) 2013-10-02 2016-11-29 Boehringer Ingelheim Vetmedica, Inc. PCV2 ORF2 protein variant and virus like particles composed thereof
US11858963B2 (en) 2013-10-02 2024-01-02 Boehringer Ingelheim Animal Health USA Inc. PCV2 ORF2 protein variant and virus like particles composed thereof
CN107589256A (zh) * 2017-09-30 2018-01-16 天津瑞普生物技术股份有限公司 副猪嗜血杆菌病4型、5型二价灭活疫苗效力的检验方法
CN113907044A (zh) * 2021-11-09 2022-01-11 福建省连江县刘氏兔业养殖场 一种抗病猪品系的培育方法及其应用

Also Published As

Publication number Publication date
CN1942204A (zh) 2007-04-04

Similar Documents

Publication Publication Date Title
WO2005112995A1 (fr) Vaccin associe inactive pour la maladie respiratoire du porc et procede de production associe
CN103536914B (zh) 多价pcv2免疫原性组合物和制备此类组合物的方法
US5597721A (en) Preparation of antigens of and of vaccines for the virus of mystery disease, antigens and vaccines obtained for the prevention of this disease
CN101175509B (zh) 含有胞内劳森菌的免疫原性组合物
EP2657333B1 (fr) Circovirus porcin de type 2, composition immunitaire contenant celui-ci, kit de dosage et utilisation de celui-ci
US20150276737A1 (en) Immunogenic compositions including SIRS virus
KR19990014840A (ko) 불가사의한 돼지의 질병과 관련된 바이러스성 약제
JP5651677B2 (ja) 各種血清型のブタ連鎖球菌（Ｓｔｒｅｐｔｏｃｏｃｃｕｓｓｕｉｓ）細菌から防御するためのワクチン
Savard et al. In vivo effect of deoxynivalenol (DON) naturally contaminated feed on porcine reproductive and respiratory syndrome virus (PRRSV) infection
KR101864029B1 (ko) 다회투여량 혼합 백신 조성물
KR101484469B1 (ko) 돼지 써코바이러스 관련 질환을 예방하기 위한 ｐｃｖ-2의 전체 바이러스를 포함하는 혼합백신
CN103127497B (zh) 猪圆环病毒2型、肺炎支原体二联灭活疫苗及其制备方法
WO2016119078A1 (fr) Utilisation combinée de la souche lc et de la souche lz-20100109 de haemophilus parasuis
WO2002062382A1 (fr) Vaccins anti-diarrheiques bovins inactives, procedes et methode de prevention des diarrhees chez les bovins
Saito et al. Attenuation of the myxoma virus and use of the living attenuated virus as an immunizing agent for myxomatosis
US5213795A (en) Encephalomyocarditis virus vaccine
KR102077701B1 (ko) 살모넬라 갈리나룸 사균체를 포함하는 가금 티푸스의 예방 또는 치료용 백신 조성물
CN101420975A (zh) 抗支原体和prrsv的疫苗
EP4272755A1 (fr) Vaccin combiné destiné à prévenir le syndrome pieds-mains-bouche, son procédé de préparation et son utilisation
CN104338128B (zh) 一种疫苗组合物及其制备方法和应用
AU775752B2 (en) Campylobacter vaccine
KR101013226B1 (ko) 개 바이러스성 설사병 예방용 백신
KR101588297B1 (ko) 액티노바실루스 플로르뉴모니애, 파스튜렐라 멀토시다 및 써코바이러스에 의한 돼지의 감염을 예방하거나 치료하기 위한 다가 백신 조성물
CN103756942B (zh) 一株大肠杆菌菌株以及将菌株灭活得到的奶牛乳房炎疫苗
CN114668792B (zh) 一种构树提取物在制备防治猪流行性腹泻病毒或猪急性腹泻综合征冠状病毒的药物中的应用

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 12006501950

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 200580011614.9

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 1200601759

Country of ref document: VN

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

122 Ep: pct application non-entry in european phase